NCT07539233 2026-04-20
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
Institute of Hematology & Blood Diseases Hospital, China
Peking University First Hospital
Suzhou Immunofoco Biotechnology Co., Ltd